RxDoctor Payments Data

Gloria Lu, MD

Family Medicine · Newport Beach, CANPI 1932589108

Payments from drug & device makers

$4,916in general payments, 2019–2025

Across 234 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$817
  • AbbVie$543
  • Boehringer Ingelheim$518
  • Lilly USA, LLC$421
  • GSK$391
  • Novo Nordisk$351
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,910100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,916 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$15,655
Medicare patients
76
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$23,988
JardianceEmpagliflozin16$19,137
Diclofenac Sodium12$956
Atorvastatin Calcium107$810
Rosuvastatin Calcium39$788
Levothyroxine Sodium50$652
Albuterol Sulfate HfaAlbuterol Sulfate18$546
Metformin Hcl51$267
Fluticasone Propionate14$244
Losartan Potassium43$241
Pravastatin Sodium28$221
Pregabalin11$210
Metoprolol Succinate30$195
Amlodipine Besylate61$166
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide14$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$817$23,98816 claims
Boehringer IngelheimJardiance$518$19,13716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →